{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001833406,0.002031585,0.002203474,0.0004491412,0.0004045715,0.0009459917,0.0008882415,0.001490613,0.00300769],"category_scores_gemma":[0.001449786,0.0006828945,0.001182155,0.0004216643,0.001068786,0.0008702534,0.0004351072,0.002585803,0.0006822603],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009642903,"about_ca_system_score_gemma":0.001770868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008363509,"about_ca_topic_score_gemma":0.001313088,"domain_scores_codex":[0.9993185,0.0003950638,0.00003380736,0.00008045247,0.00005540455,0.0001167947],"domain_scores_gemma":[0.9990004,0.0001737537,0.0001721592,0.00006527953,0.00005320887,0.0005351852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8822356,0.04273253,0.00639107,0.0003583848,0.00095717,0.0003766601,0.0002743307,0.002052594,0.0159623,0.0002401769,0.002109523,0.04630964],"study_design_scores_gemma":[0.7327421,0.2571223,0.005967911,0.00001743377,0.0001884693,0.0002088437,0.00003142519,0.001077133,0.001218969,0.00008532775,0.001324144,0.00001587918],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945775,0.001318417,0.0003202251,0.0004152946,0.0001346672,0.00160404,0.0003197512,0.00006175071,0.0012482],"genre_scores_gemma":[0.9903193,0.000974109,0.001110808,0.0007543782,0.0003713064,0.002722038,0.001805185,0.0000192356,0.001923706],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00300769,"threshold_uncertainty_score":0.01006168,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1176703880999536,"score_gpt":0.4940915774878471,"score_spread":0.3764211893878935,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}